APM News & Events

Aptorum Group announced that it has received a notification from Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550. The notification does not immediately affect the listing or trading of the company's shares on Nasdaq. Aptorum Group has been granted a 180-calendar-day grace period, until September 1 to regain compliance with the noted listing requirement. During this period, Aptorum Group intends to evaluate all available options to restore compliance, including, if necessary, a reverse stock split. The company is committed to maintaining its Nasdaq listing and will take all reasonable measures to achieve compliance within the stipulated time frame.

Aptorum Group, DiamiR Biosciences, and Instant NanoBiosensors announced a collaboration between DiamiR and INB to validate INB's automated APOE testing platform for clinical use in DiamiR's CLIA-certified, CAP-accredited clinical laboratory. Tony Chung, Chairman of Instant NanoBiosensors, stated, "We view DiamiR Biosciences as a highly respected reference laboratory. We believe that completing this validation and implementing the service together will strengthen confidence in the INB platform, expand DiamiR's validated service offerings, and establish a strong foundation for future collaboration and additional applications beyond APOE testing."

Aptorum Group files $75M mixed securities shelf